AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.
The FDA and EMA have aligned on ten guiding principles for the responsible use of artificial intelligence across the drug development lifecycle, establishing a shared framework to support innovation, ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...
Hosted on MSN
The first AI-generated drug enters clinical trials
The world of medicine has taken a significant leap forward with the first AI-generated drug entering clinical trials. This breakthrough has the potential to revolutionize drug discovery, transforming ...
The MarketWatch News Department was not involved in the creation of this content. Xtalks Life Science Podcast Wraps Up 2025 with Deep Dives into Drug Development, Regulation, Clinical Trials and ...
The Food and Drug Administration (FDA) has issued a new guidance document entitled “Enhancing Participation in Clinical Trials – Eligibility Criteria, Enrollment Practices, and Trial Decision.” The ...
In the Union Budget for FY27, the government announced plans to accredit more than 1,000 clinical trial sites to speed up drug development. Whether it works will depend on manpower and regulatory ...
The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results